Panion & BF Biotech Inc
Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, provides western medicines, cosmetics, testing reagents, food and chemical products in Taiwan, the United States, China, Hong Kong, Macau, and internationally. The company offers products in the areas of antibody, respiratory, gastrointestinal, COVID-19 IVD, antigen, anti-aging, active pharmaceutical ingredients, disease treatment,… Read more
Panion & BF Biotech Inc (1760) - Total Liabilities
Latest total liabilities as of September 2025: NT$1.22 Billion TWD
Based on the latest financial reports, Panion & BF Biotech Inc (1760) has total liabilities worth NT$1.22 Billion TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Panion & BF Biotech Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how Panion & BF Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Panion & BF Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Panion & BF Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Allied Energy Inc
PINK:AGGI
|
USA | $493.42K |
|
Aimei Health Technology Co., Ltd Ordinary Share
NASDAQ:AFJK
|
USA | $3.46 Million |
|
Namhae Chemical
KO:025860
|
Korea | ₩276.43 Billion |
|
Zhongjie (Jiangsu) Technology Co.Ltd.
SHE:301072
|
China | CN¥546.69 Million |
|
Sern Kou Resources Bhd
KLSE:7180
|
Malaysia | RM164.59 Million |
|
Zhejiang XinNong Chemical Co Ltd Class A
SHE:002942
|
China | CN¥464.76 Million |
|
Context Therapeutics Inc
NASDAQ:CNTX
|
USA | $6.06 Million |
|
Changshu Tongrun Auto
SHG:603201
|
China | CN¥1.31 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Panion & BF Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Panion & BF Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Panion & BF Biotech Inc (2009–2024)
The table below shows the annual total liabilities of Panion & BF Biotech Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.29 Billion | -2.89% |
| 2023-12-31 | NT$1.32 Billion | +21.88% |
| 2022-12-31 | NT$1.09 Billion | +6.50% |
| 2021-12-31 | NT$1.02 Billion | -44.38% |
| 2020-12-31 | NT$1.83 Billion | +231.68% |
| 2019-12-31 | NT$552.94 Million | +14.15% |
| 2018-12-31 | NT$484.38 Million | +17.53% |
| 2017-12-31 | NT$412.15 Million | +7.10% |
| 2016-12-31 | NT$384.82 Million | -3.87% |
| 2015-12-31 | NT$400.33 Million | +0.80% |
| 2014-12-31 | NT$397.15 Million | +15.46% |
| 2013-12-31 | NT$343.99 Million | -46.70% |
| 2012-12-31 | NT$645.34 Million | +1.29% |
| 2011-12-31 | NT$637.11 Million | +13.75% |
| 2010-12-31 | NT$560.10 Million | +2.05% |
| 2009-12-31 | NT$548.82 Million | -- |